Thyroid Drugs

Thyroid disorders are among the most common endocrine conditions you will encounter in clinical practice, affecting metabolic rate, cardiovascular health, and overall patient well-being. Mastery of thyroid pharmacology is not merely academic; it is a critical skill for preventing complications and tailoring therapy to individual patient needs, from lifelong hormone replacement to managing thyroid storm.

Understanding Hypothyroidism and Levothyroxine Therapy

Hypothyroidism results from insufficient production of thyroid hormone, primarily thyroxine ($T_4$). The cornerstone of treatment is levothyroxine, a synthetic form of $T_4$ that serves as hormone replacement. The goal of therapy is to replicate the body's natural thyroid function, alleviating symptoms like fatigue, weight gain, and cold intolerance. You initiate therapy at a low dose, typically 1.6 µg/kg of ideal body weight per day, and the standard monitoring parameter is the Thyroid-Stimulating Hormone (TSH) level. A normalized TSH, usually between 0.5 and 2.5 mIU/L for most patients, indicates adequate replacement and is the primary target for dose adjustment.

A critical pharmacokinetic consideration is that levothyroxine absorption occurs primarily in the jejunum and ileum and is notoriously susceptible to interference. Cations such as calcium (found in supplements and antacids) and iron (in multivitamins and ferrous sulfate) can form insoluble complexes with levothyroxine in the gut, drastically reducing its bioavailability. Therefore, you must instruct patients to take levothyroxine on an empty stomach, at least 30-60 minutes before breakfast, and to separate it from these interfering substances by at least 4 hours. Consider a patient who presents with a rising TSH despite compliance; your first question should be about recent changes in calcium or iron intake.

Dose titration requires special caution in vulnerable populations. In elderly patients and those with known cardiac disease, the metabolic surge from initiating thyroid hormone can precipitate angina, atrial fibrillation, or even myocardial infarction. The principle here is "start low and go slow." For an elderly patient with subclinical hypothyroidism, you might begin with 25 µg daily, or even 12.5 µg, and increase by 25 µg increments every 6-8 weeks only after assessing TSH and clinical tolerance. This cautious approach minimizes cardiovascular strain while still achieving therapeutic goals.

Pharmacology of Antithyroid Medications for Hyperthyroidism

Hyperthyroidism, most commonly from Graves' disease, involves excessive thyroid hormone production. The first-line thioamide drugs, methimazole and propylthiouracil (PTU), work by inhibiting the enzyme thyroid peroxidase. This enzyme is crucial for the oxidation and organification of iodide and the coupling of iodotyrosines to form $T_3$ and $T_4$. By blocking this process, these drugs reduce the synthesis of new thyroid hormone within the gland itself.

While both drugs share this core mechanism, PTU has an additional, unique action: it inhibits the peripheral conversion of $T_4$ to the more active triiodothyronine ($T_3$) by type 1 deiodinase. This makes PTU the preferred agent in specific high-stakes scenarios. Most notably, during the first trimester of pregnancy, PTU is favored because methimazole has been associated with a rare risk of fetal abnormalities, such as aplasia cutis. However, due to a higher risk of severe hepatotoxicity with PTU, therapy is often switched to methimazole after the first trimester. This nuanced decision-making is a key example of balancing drug efficacy with patient-specific risks.

A serious adverse effect common to both thioamides is agranulocytosis, a potentially life-threatening drop in neutrophil count. This is an idiosyncratic reaction, typically occurring within the first three months of therapy. You must educate patients to immediately report signs of infection like fever, sore throat, or mouth ulcers. Routine complete blood count monitoring is not universally recommended due to the reaction's rapid onset, but a baseline CBC is prudent, and any sign of infection warrants an urgent white blood cell count with differential. If agranulocytosis is confirmed, the drug must be discontinued permanently and the patient managed supportively.

Radioactive Iodine Ablation: Mechanism and Indications

For definitive treatment of hyperthyroidism, especially in patients who cannot tolerate or fail antithyroid drugs, radioactive iodine ablation (${}^{131}I$) is a highly effective option. The mechanism is elegantly specific: the thyroid gland actively traps iodine from the bloodstream to synthesize hormone. When you administer the radioisotope ${}^{131}I$, it is concentrated within thyroid follicular cells just like stable iodine. The emitted beta radiation then destroys the hyperfunctioning tissue over a period of weeks to months through localized cytotoxic effects. The goal is to render the patient hypothyroid, which is then easily managed with levothyroxine replacement. It is contraindicated in pregnancy and breastfeeding, and patients must follow radiation safety precautions post-treatment.

Clinical Considerations and Integrated Management

Effective management extends beyond prescribing. You must integrate monitoring with lifestyle and comorbidity considerations. For instance, a patient on stable levothyroxine who starts a proton pump inhibitor for GERD may experience altered gastric acidity affecting absorption, necessitating a TSH check in 6-8 weeks. Similarly, managing a thyroid storm requires a multi-pronged approach: high-dose PTU (for $T_4$ to $T_3$ conversion block), beta-blockers for adrenergic symptoms, iodine solutions to inhibit hormone release, and corticosteroids. Always remember that therapy is dynamic; conditions like pregnancy, aging, and the onset of new diseases like celiac disease will require re-evaluation of thyroid drug dosing and monitoring intervals.

Common Pitfalls

1. Ignoring Drug-Drug and Drug-Food Interactions: Prescribing levothyroxine without counseling on calcium and iron separation is a common error. Correction: Always provide clear, written instructions to take levothyroxine alone with water, first thing in the morning, and to space interfering medications or supplements by at least 4 hours.
2. Overly Rapid Titration in High-Risk Patients: Aggressively normalizing TSH in an elderly patient with coronary artery disease can trigger cardiac ischemia. Correction: Adhere to a conservative titration schedule, increasing doses by no more than 25 µg every 6-8 weeks while monitoring for cardiac symptoms.
3. Misunderstanding First-Trimester Antithyroid Choice: Using methimazole as first-line in a newly pregnant patient with hyperthyroidism increases fetal risk. Correction: Initiate therapy with PTU during the first trimester, with plans to transition to methimazole thereafter, while closely monitoring liver function.
4. Failing to Recognize Agranulocytosis Symptoms: Attributing a sore throat in a patient on methimazole to a simple cold can delay lifesaving intervention. Correction: Drill into patients the "sore throat/fever" warning signs and ensure they understand the need for immediate medical evaluation and a CBC.

Summary

• Levothyroxine is life-long replacement for hypothyroidism, dosed to normalize the TSH level. Its absorption is significantly impaired by calcium and iron, requiring careful timing of administration.
• Antithyroid drugs methimazole and PTU act by inhibiting thyroid peroxidase. PTU is preferred in the first trimester of pregnancy due to its additional block of peripheral $T_4$ to $T_3$ conversion, though both carry a risk of agranulocytosis.
• Radioactive iodine ablation works via beta-radiation emitted from concentrated ${}^{131}I$, selectively destroying thyroid tissue to definitively treat hyperthyroidism.
• Dose titration must be exceptionally cautious in the elderly and cardiac patients to avoid precipitating cardiovascular events.
• Successful management hinges on patient education about drug interactions and serious adverse effects, coupled with consistent biochemical monitoring.